Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Supports Earlier Lupus Diagnosis

Published: Friday, May 10, 2013
Last Updated: Friday, May 10, 2013
Bookmark and Share
Superior sensitivity and specificity compared to current laboratory tests.

Oxford Gene Technology (OGT) has announced the development of a novel autoantibody biomarker panel for improved diagnosis of systemic lupus erythematosus (SLE).
 
The panel has been developed in partnership with King’s College London, utilising OGT’s proprietary protein array platform technology. The platform detects autoantibodies, a class of proteins that have been shown to precede clinical symptoms of SLE by several years1. It also accurately distinguishes between SLE and ‘confounding diseases’ such as rheumatoid arthritis.
 
The biomarker panel, which was originally identified using a North American sample cohort, has been rigorously validated in two independent sample cohorts comprising over 450 European, Afro-Caribbean, and confounding disease samples. The panel maintains a high sensitivity and specificity across all cohorts studied.
 
SLE affects at least five million people worldwide, over 90% of whom are women. The figure may be higher as SLE is notoriously challenging to diagnose with widely variable symptoms which are inconsistent in patients. Current diagnosis is usually performed by comparing a patient’s symptoms against 11 pre-set criteria established by the American College of Rheumatology. If the patient presents any four of the symptoms simultaneously or serially on two separate occasions, they are classified as having SLE. Typically it takes several years and the involvement of many clinicians to diagnose an SLE patient.
 
Existing laboratory tests include antinuclear antibody (ANA) testing and anti-double stranded DNA (anti-dsDNA) testing but their specificity or sensitivity is too low to support the diagnosis or classification of SLE without additional data. The OGT panel would allow for earlier and more accurate diagnosis than existing tests addressing a clear unmet medical need.
 
Dr Mike Evans, CEO at OGT said, “SLE is a truly debilitating disease that is particularly challenging to diagnose. Our novel diagnostic biomarker panel is more sensitive and specific than existing laboratory tests and it is our hope that, by correctly identifying the presence of SLE at an earlier stage, patients will receive faster access to the most appropriate treatment. We are pleased with the progress of our biomarker portfolio, which also includes advanced programmes in prostate and colorectal cancer, and we are currently evaluating potential partners to develop diagnostic tests based on the SLE biomarkers.”
 
Professor Tim Vyse, Division of Genetics and Molecular Medicine at King’s College London said: “The OGT SLE panel represents a big step forward in lupus genetic testing and the outcome of the programme so far has been very encouraging.”
 
OGT is also in discussions with SLE drug developers regarding potential prognostic applications of the biomarkers set to predict the occurrence and frequency of relapse, or ‘flares’, so that treatment regimens can be adjusted accordingly and patient well-being maximised.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Initiates Clinical Trial of New Array-Based NIPT
Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.
Tuesday, November 04, 2014
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012
The conference will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre.
Friday, February 10, 2012
OGT Founder Professor Sir Ed Southern Awarded the 2011 MRC Millennium Medal
Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis.
Monday, January 30, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Featured in the Sunday Times Biotech Supplement
The article entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations will help push healthcare costs down, while improving the accuracy of early disease diagnosis.
Monday, January 24, 2011
OGT Announces Major Role in Large Scale Diabetes Study
Genefficiency™ aCGH microarray service to process extensive sample set linking CNVs to disease susceptibility.
Thursday, December 02, 2010
OGT Receives ISO/IEC 27001:2005 Accreditation
Certification highlights commitment to information security and confidentiality.
Thursday, September 16, 2010
OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010
Delegates heard presentations on how OGT’s array comparative genomic hybridization solutions can help advance disease and cytogenetics research.
Tuesday, July 13, 2010
OGT to Present at International Workshop on the Search for New IVD Biomarkers
Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Wednesday, June 16, 2010
Scientific News
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
£14m EU Project To Aid Meningitis Diagnosis and Cut Antibiotic Use
An international team of doctors are aiming to develop a rapid test to allow medics to quickly identify bacterial infection in children.
Bringing AFM to Medical Diagnostics
Company has announced that its NanoWizard® AFM and ForceRobot® systems are being used in the field of medical diagnostics in the Supersensitive Molecular Layer Laboratory of POSTECH in Korea.
Scientific Gains May Make Electronic Nose the Next Everyday Device
UT Dallas team breathes new life into possibilities by using CMOS integrated circuits technology.
Electronic Sensor Tells Dead Bacteria From Live
The sensor, which measures 'osmoregulation', is a potential future tool for medicine and food safety.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Genome Sequencing Helps Determine End of TB Outbreak
Using genome sequencing, researchers from the University of British Columbia, along with colleagues at the Imperial College in London, now have the ability to determine when a tuberculosis (TB) outbreak is over.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Shimmer Partners with Harvard's Wyss Institute
Partnership to support ongoing research focused on remote patient monitoring using wearable sensing technology.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!